FOLH1 and prostate cancer: investigated 291 patients for whom MRI, pelvic prostate-specific membrane antigen PET, and systematic or targeted transperineal biopsy were performed and concluded that on the basis of the high detection rate of clinically significant prostate cancer and the high negative predictive value, “further randomised studies will determine whether biopsy can safely be omitted in men with high clinical suspicion of [clinically significant prostate cancer] but negative combined imaging”(5).